updat set stage vision
report result exceed top- bottom-lin expect busi
updat highlight sever import driver perform includ
stabl revenu base grow otezla integr deal close
manufactur effici off-set net price pressur result potenti flat gross
margin invest continu sg spend ex-u commerci
buildout could lower oper margin slightli continu progress patient
access repatha aimovig may lead inflect launch trajectori key
pipelin readout includ bite molecul tezepelumab may provid
meaning catalyst strong cash flow gener support capit alloc
may unlock addit sharehold valu busi develop share
repurchas maintain outperform pt detail insid
revenu outpac estim consensu estimate
top-lin beat driven larg enbrel vs consensu
estimate higher expect spend partli off-set light sg bottom line
bolster lower expect share count share repurchas vs
estimate lead adj -ep vs consensu exhibit
otezla acquisit expect close add revenu
peak expect grow sale
next five year driven volum label expans strateg rational
potenti oper leverag behind otezla deal exemplifi disciplin
enbrel patent legal victori support sale estim
earli data encourag may support rapid file strategi
data updat expect single-arm open-label nsclc
enrol data expect next year combin plan progress
trial antibodi underway nsclc
initi mek inhibitor combo studi may also initi
repatha deliv strong volum growth driven improv us commerci
adopt patient access expect hold market share
despit potenti competitor view biosimilar under-appreci option
three already-approv plu anoth bsufa date
biosimilar contribut revenu annual
strong eu uptak recent us launch
manag rais narrow financi guidanc updat model
base actual guidanc view differenti pipelin
driver margin expans post recent spend reflect strateg approach
 increas vs sg valu pipelin asset base
sotp analysi dcf valuat support pt exhibit
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
year price histori
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel flat
next year margin continu expand
manag track record financi disciplin
top line believ posit maintain long-term
revenu stabil matur product declin new product
continu grow pipelin deliv steadi flow new
product addit offer dividend yield
believ provid valuat support
updat data kra inhibitor major
updat data bcma bite
data bcma hle bite
data bite
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top line essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
exhibit actual vs oppenheim consensu estim
exhibit revenu forecast increas steadili
incom growth oppenheimerest vs oppenheim consensu estimate actual vs consensu actual oppenheim estimate vs consensu updat midpoint total non-gaap cog margin rate incom ep growth oppenheimerest vs oppenheim consensu estimate actual vs consensu actual oppenheim estimate vs consensu revenu estim pipelinehpt secondari ckdprimari caredenosumaboncologyauto-immunegrowth factorsoth inc
exhibit valu pipelin asset tezepelumab omecamtiv
base hypothet sotp analysi
exhibit dcf valuat support pt
drug/indicationexpect launchpeak sale estim mm npv mm estimate probabl successprob-adjust npv mm sotp p-adj valu sharegrowth hpt secondari equiti share outstand use valuat oppenheim co discount analysi except per-shar data revenu chang work work capit valu growth valu oppenheim estim compani reportsequ valu per sharetermin valu growth rate outperform
